The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition

Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling

(2020) Tianjun Hu et al.   ANTI-CANCER DRUGS

An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates

(2020) Jermaine Goveia et al.   CANCER CELL

Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis

(2020) Katerina Rohlenova et al.   Cell Metabolism

The clinical significance of CXCL16 in the treatment of advanced non‐small cell lung cancer

(2020) Yuji Shibata et al.   Thoracic Cancer

Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients

(2020) Lupeng Qiu et al.   MEDICINE

Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects

(2020) Catherine Overed-Sayer et al.   THORAX

Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors

(2020) Kayoko Hosaka et al.   Nature Communications

The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody With bFGF/VEGFA

(2020) Ligang Zhang et al.   Frontiers in Oncology

Therapeutic angiogenesis: From conventional approaches to recent nanotechnology-based interventions

(2019) Robin Augustine et al.   Materials Science & Engineering C-Materials for Biological Applications

Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells

(2019) Jun Lu et al.   BMC Medical Genomics

Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial

(2019) Haruhiro Saito et al.   LANCET ONCOLOGY

Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice

(2019) Yushu Joy Xie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy

(2019) Iris Uribesalgo et al.   EMBO Molecular Medicine

miR‑195 suppresses metastasis and angiogenesis of squamous cell lung cancer by inhibiting the expression of VEGF

(2019) Hailin Liu et al.   Molecular Medicine Reports

MicroRNA-130b functions as an oncomiRNA in non-small cell lung cancer by targeting tissue inhibitor of metalloproteinase-2

(2019) Takayuki Hirono et al.   Scientific Reports

Hallmarks of Endothelial Cell Metabolism in Health and Disease

(2019) Xuri Li et al.   Cell Metabolism

Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial

(2019) Roy S Herbst et al.   LANCET ONCOLOGY

Targeting Tumor Endothelial Cells with Nanoparticles

(2019) Sakurai et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo

(2019) Kristina Petrovic et al.   PLoS One

Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment

(2019) Dorcas A. Annan et al.   Cell Communication and Signaling

Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Kazuhiko Nakagawa et al.   LANCET ONCOLOGY

Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment

(2019) Raluca Ioana Teleanu et al.   Journal of Clinical Medicine

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

(2018) Baohui Han et al.   BRITISH JOURNAL OF CANCER

Antiangiogenic therapies in non-small-cell lung cancer

(2018) A. Alshangiti et al.   Current Oncology

The regulatory role of microRNAs in angiogenesis-related diseases

(2018) Li-Li Sun et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis

(2018) Silvia La Porta et al.   JOURNAL OF CLINICAL INVESTIGATION

Phenotype molding of stromal cells in the lung tumor microenvironment

(2018) Diether Lambrechts et al.   NATURE MEDICINE

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

The dark side of tumor-associated endothelial cells

(2018) Francesco De Sanctis et al.   SEMINARS IN IMMUNOLOGY

Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease

(2018) Dhruv R. Seshadri et al.   Frontiers in Pharmacology

Anti-Angiogenics: Their Value in Lung Cancer Therapy

(2018) Melanie Janning et al.   Oncology Research and Treatment

TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer

(2018) AKIRA TAKEUCHI et al.   ANTICANCER RESEARCH

Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation

(2018) Ulrike Bruning et al.   Cell Metabolism

Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.

(2018) Noboru Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma

(2018) Tianrun Liu et al.   Nature Communications

Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer

(2018) Cesare Gridelli et al.   JAMA Oncology

Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer

(2018) Baohui Han et al.   JAMA Oncology

Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy

(2018) Jun Lu et al.   EUROPEAN RESPIRATORY JOURNAL

The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms

(2018) Yun Xia et al.   INTERNATIONAL JOURNAL OF CANCER

Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer

(2017) Martin Reck et al.   LUNG CANCER

Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin

(2017) Daniel Delgado-Bellido et al.   Molecular Cancer

Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1

(2017) Y-L Hsu et al.   ONCOGENE

Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer

(2017) Nusrat Chowdhury et al.   PHARMACEUTICAL RESEARCH

Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade

(2017) Martina Schmittnaegel et al.   Science Translational Medicine

Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation

(2017) Elizabeth Allen et al.   Science Translational Medicine

Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B

(2017) M. Wroblewski et al.   Nature Communications

Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy

(2016) Anna Rita Cantelmo et al.   CANCER CELL

Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects

(2016) Dong Li et al.   CANCER LETTERS

Cell behaviors and dynamics during angiogenesis

(2016) Charles Betz et al.   DEVELOPMENT

Tumor angiogenesis—characteristics of tumor endothelial cells

(2016) Kyoko Hida et al.   International Journal of Clinical Oncology

Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation

(2016) Minah Kim et al.   JOURNAL OF CLINICAL INVESTIGATION

Tie1 controls angiopoietin function in vascular remodeling and inflammation

(2016) Emilia A. Korhonen et al.   JOURNAL OF CLINICAL INVESTIGATION

Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models

(2016) Victoria L Bridgeman et al.   JOURNAL OF PATHOLOGY

Antiangiogenic therapy in oncology: current status and future directions

(2016) Gordon C Jayson et al.   LANCET

Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer

(2016) Analia Rodríguez Garzotto et al.   MEDICAL ONCOLOGY

Angiocrine functions of organ-specific endothelial cells

(2016) Shahin Rafii et al.   NATURE

Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets

(2016) Yufang Shi et al.   NATURE REVIEWS DRUG DISCOVERY

Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages

(2016) Teresa E. Peterson et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Vasculogenic mimicry in small cell lung cancer

(2016) Stuart C. Williamson et al.   Nature Communications

Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism

(2016) Yunlong Yang et al.   Nature Communications

Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?

(2016) Ana Luísa Coelho et al.   Oncotarget

When tumors are (co-)opting to resist anti-angiogenic treatment

(2016) Lasse D. Jensen   Translational Cancer Research

VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy

(2015) M. Schwaederle et al.   CANCER RESEARCH

Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer

(2015) Silvia Novello et al.   EUROPEAN JOURNAL OF CANCER

Tryptase, a novel angiogenic factor stored in mast cell granules

(2015) Domenico Ribatti et al.   EXPERIMENTAL CELL RESEARCH

Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo

(2015) Jasmine G. Lee et al.   NEOPLASIA

Understanding high endothelial venules: Lessons for cancer immunology

(2015) Ann Ager et al.   OncoImmunology

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)

(2014) Tony Mok et al.   Journal of Thoracic Oncology

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

(2014) Edward B Garon et al.   LANCET

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

(2014) Martin Reck et al.   LANCET ONCOLOGY

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Functional polarization of tumour-associated macrophages by tumour-derived lactic acid

(2014) Oscar R. Colegio et al.   NATURE

Glioblastoma: A Pathogenic Crosstalk between Tumor Cells and Pericytes

(2014) Elisabetta M. Caspani et al.   PLoS One

Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade

(2014) Nicolò Rigamonti et al.   Cell Reports

Role of PFKFB3-Driven Glycolysis in Vessel Sprouting

(2013) Katrien De Bock et al.   CELL

Strategies for advancing cancer nanomedicine

(2013) Vikash P. Chauhan et al.   NATURE MATERIALS

Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

(2013) Tom Donnem et al.   Cancer Medicine

Regulation of tumor-associated high-endothelial venules by dendritic cells

(2013) Ludovic Martinet et al.   OncoImmunology

Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer

(2012) J.-C. Soria et al.   ANNALS OF ONCOLOGY

Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs

(2012) Astrid A.M. Van der Veldt et al.   CANCER CELL

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Bradykinin Promotes the Chemotactic Invasion of Primary Brain Tumors

(2011) V. Montana et al.   JOURNAL OF NEUROSCIENCE

Molecular mechanisms and clinical applications of angiogenesis

(2011) Peter Carmeliet et al.   NATURE

Angiogenesis

(2011) D. R. Senger et al.   Cold Spring Harbor Perspectives in Biology

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

(2010) M. Reck et al.   ANNALS OF ONCOLOGY

Mast cells, angiogenesis, and tumour growth

(2010) Domenico Ribatti et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Signalling pathways in vasculogenic mimicry

(2010) Yvette W.J. Paulis et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature

(2010) De-Hong Yu et al.   BIOMATERIALS

Matrix Metalloproteinases: Regulators of the Tumor Microenvironment

(2010) Kai Kessenbrock et al.   CELL

Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study

(2010) Lucio Crinò et al.   LANCET ONCOLOGY

Inositol-requiring enzyme 1  is a key regulator of angiogenesis and invasion in malignant glioma

(2010) G. Auf et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy

(2009) S. J. Priceman et al.   BLOOD

An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients

(2009) Balazs Györffy et al.   BREAST CANCER RESEARCH AND TREATMENT

PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment

(2009) Yongping Crawford et al.   CANCER CELL

Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy — Association of interleukin-8 and VEGF with survival

(2009) Marika Crohns et al.   CYTOKINE

Angiogenesis in pre-malignant conditions

(2009) Marius Raica et al.   EUROPEAN JOURNAL OF CANCER

Mast cell phenotypes and microvessels in non–small cell lung cancer and its prognostic significance

(2009) María José Carlini et al.   HUMAN PATHOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system

(2009) Hellmut G. Augustin et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment

(2008) B. Huang et al.   BLOOD

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non-Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab--an Eastern Cooperative Oncology Group Study

(2008) A. Dowlati et al.   CLINICAL CANCER RESEARCH